Meeting
2017 Gastrointestinal Cancers Symposium
KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.
Authors
Luis A. Diaz Jr.
Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD
Luis A. Diaz Jr., Dung T. Le , Takayuki Yoshino , Thierry Andre , Johanna C. Bendell , Minori Koshiji , Yinghua Zhang , S. Peter Kang , Baohoang Lam , Dirk Jäger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02563002
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS815)
DOI
10.1200/JCO.2017.35.4_suppl.TPS815
Abstract #
TPS815
Poster Bd #
O15
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
KEYNOTE-177: first-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.
Poster
2016 Gastrointestinal Cancers Symposium
KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.
Poster
2018 Gastrointestinal Cancers Symposium
Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
First Author: Luis A. Diaz Jr.
Poster
2017 ASCO Annual Meeting
Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.
First Author: Luis A. Diaz Jr.